Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Phase 2 Active not recruiting 36 enrolled Michael Peluso, MD Aerium Therapeutics · collab Patient-Led Research Collaborative · collab PolyBio Research Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Timeline

Start: 2023-08-01
Primary completion: 2024-07-29
Completion: 2026-07-31

Publications

Peluso MJ, Hanson MR, Deeks SG. Infection-associated chronic conditions: Why Long Covid is our best chance to untangle Osler's web. Sci Transl Med. 2024 Nov 13;16(773):eado2101. doi: 10.1126/scitranslmed.ado2101. Epub 2024 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ulinastatin	Protein / enzyme biologic	1200 mg	Intravenous

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Summary

Timeline

Publications

Drugs

Indications